Skip to main content
Top
Published in: Acta Diabetologica 5/2014

01-10-2014 | Original Article

High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects

Authors: G. Sesti, F. Andreozzi, T. V. Fiorentino, G. C. Mannino, A. Sciacqua, M. A. Marini, F. Perticone

Published in: Acta Diabetologica | Issue 5/2014

Login to get access

Abstract

Irisin, a novel myokine, was proposed to be able to regulate glucose homeostasis and obesity in mice. Whether irisin levels are associated with cardio-metabolic variables, insulin sensitivity, and vascular atherosclerosis in humans remain unsettled. To determine the associations between circulating irisin levels, cardio-metabolic variables, insulin sensitivity, and common carotid intima-media thickness (IMT), an indicator of vascular atherosclerosis, a cross-sectional evaluation of circulating irisin levels and cardio-metabolic variables in 192 White adults was conducted. Insulin sensitivity and insulin clearance were assessed by euglycemic–hyperinsulinemic clamp. Common carotid IMT was measured by ultrasound. After adjusting for age and gender, irisin levels were positively correlated with body fat mass (r = 0.12, P < 0.05), fasting (r = 0.17, P < 0.01), 2 h post-load insulin (r = 0.15, P < 0.02) levels, and IMT (r = 0.29, P < 0.0001) and were negatively correlated with insulin-stimulated glucose disposal (r = −0.18, P = 0.007), Matsuda index (r = −0.13, P < 0.04), disposition index (r = −0.278, P < 0.0001), and insulin clearance (r = −0.26, P < 0.0001). After adjusting for age, gender, and BMI, individuals in the highest tertile of irisin levels exhibited higher body fat mass (P < 0.01), fasting (P < 0.05), 2 h post-load (P < 0.01) insulin levels, carotid IMT (P < 0.001), lower insulin-stimulated glucose disposal (P < 0.001), Matsuda index (P < 0.01), disposition index (P < 0.01), and insulin clearance (P < 0.001) as compared with subjects in the lowest tertile of circulating irisin levels. Irisin is inversely associated with insulin sensitivity and positively associated with carotid IMT in humans, suggesting either increased release by adipose/muscle tissue in response to deterioration of insulin sensitivity or a compensatory increase in irisin to overcome an underlying irisin resistance.
Literature
1.
go back to reference Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief 82:1–8PubMed Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief 82:1–8PubMed
2.
go back to reference Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed
3.
go back to reference Prospective Studies Collaboration, Whitlock G, Lewington S et al (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 73:1083–1096 Prospective Studies Collaboration, Whitlock G, Lewington S et al (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 73:1083–1096
4.
go back to reference Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91:2906–2912CrossRefPubMed Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91:2906–2912CrossRefPubMed
5.
go back to reference Arnlöv J, Ingelsson E, Sundström J, Lind L (2010) Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121(2):230–236CrossRefPubMed Arnlöv J, Ingelsson E, Sundström J, Lind L (2010) Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121(2):230–236CrossRefPubMed
6.
go back to reference Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778CrossRefPubMed Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778CrossRefPubMed
8.
go back to reference Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
9.
go back to reference Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465CrossRefPubMed Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465CrossRefPubMed
10.
go back to reference Boström P, Wu J, Jedrychowski MP et al (2012) A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468CrossRefPubMedCentralPubMed Boström P, Wu J, Jedrychowski MP et al (2012) A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468CrossRefPubMedCentralPubMed
11.
go back to reference Timmons JA, Baar K, Davidsen PK, Atherton PJ (2012) Is irisin a human exercise gene? Nature 488:E9–E10CrossRefPubMed Timmons JA, Baar K, Davidsen PK, Atherton PJ (2012) Is irisin a human exercise gene? Nature 488:E9–E10CrossRefPubMed
12.
go back to reference Huh JY, Panagiotou G, Mougios V et al (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725–1738CrossRefPubMedCentralPubMed Huh JY, Panagiotou G, Mougios V et al (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725–1738CrossRefPubMedCentralPubMed
13.
go back to reference Hee Park K, Zaichenko L, Brinkoetter M et al (2013) Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98:4899–4907CrossRef Hee Park K, Zaichenko L, Brinkoetter M et al (2013) Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98:4899–4907CrossRef
14.
go back to reference Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 39:125–130CrossRefPubMed Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 39:125–130CrossRefPubMed
15.
go back to reference Liu JJ, Wong MD, Toy WC et al (2013) Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 27:365–369CrossRefPubMed Liu JJ, Wong MD, Toy WC et al (2013) Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 27:365–369CrossRefPubMed
16.
go back to reference Moreno-Navarrete JM, Ortega F, Serrano M et al (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769–E778CrossRefPubMed Moreno-Navarrete JM, Ortega F, Serrano M et al (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769–E778CrossRefPubMed
17.
go back to reference Choi YK, Kim MK, Bae KH et al (2013) Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96–101CrossRefPubMed Choi YK, Kim MK, Bae KH et al (2013) Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96–101CrossRefPubMed
18.
go back to reference Staiger H, Böhm A, Scheler M et al (2013) Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived ‘browning’ factor irisin, determines insulin sensitivity. PLoS One 25(8):e61903CrossRef Staiger H, Böhm A, Scheler M et al (2013) Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived ‘browning’ factor irisin, determines insulin sensitivity. PLoS One 25(8):e61903CrossRef
19.
go back to reference Staiger H, Stančáková A, Zilinskaite J et al (2008) A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 57:514–517CrossRefPubMed Staiger H, Stančáková A, Zilinskaite J et al (2008) A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 57:514–517CrossRefPubMed
20.
go back to reference Stancáková A, Pihlajamäki J, Kuusisto J et al (2008) SNP rs7754840 of CDKAL1 is associated with impaired insulin secretion in non-diabetic offspring of type 2 diabetic subjects (the EUGENE2 study) and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 93:1924–1930CrossRefPubMed Stancáková A, Pihlajamäki J, Kuusisto J et al (2008) SNP rs7754840 of CDKAL1 is associated with impaired insulin secretion in non-diabetic offspring of type 2 diabetic subjects (the EUGENE2 study) and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 93:1924–1930CrossRefPubMed
21.
go back to reference Marini MA, Succurro E, Frontoni S et al (2012) Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-h postload plasma glucose levels. Diabetes Care 35:868–872CrossRefPubMedCentralPubMed Marini MA, Succurro E, Frontoni S et al (2012) Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-h postload plasma glucose levels. Diabetes Care 35:868–872CrossRefPubMedCentralPubMed
22.
go back to reference Marini MA, Frontoni S, Mineo D et al (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371CrossRefPubMed Marini MA, Frontoni S, Mineo D et al (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371CrossRefPubMed
23.
go back to reference Succurro E, Marini MA, Arturi F et al (2009) Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207:245–249CrossRefPubMed Succurro E, Marini MA, Arturi F et al (2009) Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207:245–249CrossRefPubMed
24.
go back to reference Marini MA, Frontoni S, Succurro E et al (2013) Insulin clearance is associated with carotid artery intima–media thickness. Atherosclerosis 229:453–458CrossRefPubMed Marini MA, Frontoni S, Succurro E et al (2013) Insulin clearance is associated with carotid artery intima–media thickness. Atherosclerosis 229:453–458CrossRefPubMed
25.
go back to reference Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89–94CrossRefPubMed Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89–94CrossRefPubMed
26.
go back to reference The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167 CrossRef The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167 CrossRef
27.
go back to reference Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C (1981) Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 53:618–621CrossRefPubMed Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C (1981) Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 53:618–621CrossRefPubMed
28.
go back to reference Marini MA, Frontoni S, Succurro E et al (2013) Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One 8:e77440CrossRefPubMedCentralPubMed Marini MA, Frontoni S, Succurro E et al (2013) Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One 8:e77440CrossRefPubMedCentralPubMed
29.
go back to reference Mittelman SD, Van Citters GW, Kim SP et al (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β cell response. Diabetes 49:2116–2125CrossRefPubMed Mittelman SD, Van Citters GW, Kim SP et al (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β cell response. Diabetes 49:2116–2125CrossRefPubMed
30.
go back to reference O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22CrossRefPubMed O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22CrossRefPubMed
31.
go back to reference Nigro J, Osman N, Dart AM, Little PJ (2006) Insulin resistance and atherosclerosis. Endocr Rev 27:242–259CrossRefPubMed Nigro J, Osman N, Dart AM, Little PJ (2006) Insulin resistance and atherosclerosis. Endocr Rev 27:242–259CrossRefPubMed
32.
go back to reference Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R (2004) Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen activated protein-kinase. Diabetologia 47:532–536CrossRefPubMed Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R (2004) Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen activated protein-kinase. Diabetologia 47:532–536CrossRefPubMed
33.
go back to reference Madonna R, De Caterina R (2009) Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb Haemost 101:345–350PubMed Madonna R, De Caterina R (2009) Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb Haemost 101:345–350PubMed
34.
go back to reference Koh YJ, Park BH, Park JH, Han J, Lee IK, Park JW, Koh GY (2009) Activation of PPARγ induces profound multilocularization of adipocytes in adult mouse white adipose tissues. Exp Mol Med 41:880–895CrossRefPubMedCentralPubMed Koh YJ, Park BH, Park JH, Han J, Lee IK, Park JW, Koh GY (2009) Activation of PPARγ induces profound multilocularization of adipocytes in adult mouse white adipose tissues. Exp Mol Med 41:880–895CrossRefPubMedCentralPubMed
35.
go back to reference Daniele G, Guardado Mendoza R et al (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131CrossRefPubMed Daniele G, Guardado Mendoza R et al (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131CrossRefPubMed
36.
go back to reference Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56:2153–2163CrossRefPubMed Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56:2153–2163CrossRefPubMed
Metadata
Title
High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects
Authors
G. Sesti
F. Andreozzi
T. V. Fiorentino
G. C. Mannino
A. Sciacqua
M. A. Marini
F. Perticone
Publication date
01-10-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0576-0

Other articles of this Issue 5/2014

Acta Diabetologica 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.